Rapport Therapeutics’ (NASDAQ:RAPP) Lock-Up Period To Expire Tomorrow

Rapport Therapeutics’ (NASDAQ:RAPP) lock-up period is set to expire on Wednesday, December 4th. Rapport Therapeutics had issued 8,000,000 shares in its initial public offering on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Rapport Therapeutics Stock Performance

Shares of RAPP stock opened at $24.00 on Tuesday. Rapport Therapeutics has a 12-month low of $16.55 and a 12-month high of $29.74. The business’s fifty day simple moving average is $23.12.

Institutional Investors Weigh In On Rapport Therapeutics

Large investors have recently modified their holdings of the business. Barclays PLC boosted its stake in Rapport Therapeutics by 36.8% in the 3rd quarter. Barclays PLC now owns 12,863 shares of the company’s stock worth $264,000 after purchasing an additional 3,463 shares in the last quarter. Geode Capital Management LLC purchased a new position in shares of Rapport Therapeutics in the third quarter worth $4,133,000. State Street Corp acquired a new stake in shares of Rapport Therapeutics during the third quarter worth $1,189,000. Maven Securities LTD purchased a new stake in shares of Rapport Therapeutics during the third quarter valued at $613,000. Finally, Eventide Asset Management LLC increased its position in shares of Rapport Therapeutics by 120.8% in the 3rd quarter. Eventide Asset Management LLC now owns 110,401 shares of the company’s stock valued at $2,261,000 after acquiring an additional 60,401 shares during the period.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.